While genomic classifier (GC) tests may influence risk and treatment decisions for patients with localised prostate cancer (PCa), there is a need for better data on...
Prostate cancer remains a global health challenge, ranking as the second most commonly diagnosed cancer among men. Although treatments like androgen deprivation therapy have been effective...
The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically changed in recent years. However, aside from drug or hormonal therapies,...
Increasing percentages of some older U.S. men with intermediate-risk and high-risk prostate cancers are undergoing treatments that carry risks of side effects that can significantly reduce...
Researchers at Case Western Reserve University and Vanderbilt University are pioneering a new approach to prostate cancer surgery by combining advanced robotics and “low-field” MRI technology....
Researchers have uncovered a key reason why a typically normal protein – NSD2 – goes awry and fuels prostate cancer. They found the protein NSD2 alters...
A novel combination prostate cancer therapy has been approved by the US Food and Drug Administration. The new treatment combines two Pfizer-produced cancer drugs, Xtandi (also...
Scientists have moved a step closer to genetically personalised prostate cancer screening. The most common assessment test for the cancer, which mainly affects men over the...
Scientists researching an ‘ancient virus’ treatment for metastatic prostate cancer have been awarded $1.7 million by the US Department for Defense. Oncology expert Charles Spruck’s laboratory...
A new drug combo has been shown to boost metastasis-free survival by 58% in prostate cancer patients at high risk of biochemical recurrence. Astellas Pharma and...
